RAPT Therapeutics, Inc.

RAPT Therapeutics operates as a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule therapies targeting immunology pathways. The company concentrates on two primary therapeutic areas: inflammatory diseases and oncology. Its lead inflammation candidate is zelnecirnon (RPT193), a CCR4 antagonist designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. In oncology, the company is advancing tivumecirnon (FLX475), also a CCR4 antagonist, which is currently in Phase 1/2 clinical trials as both a monotherapy and in combination with pembrolizumab for patients with advanced cancer.

The company operates from its headquarters in South San Francisco, California, with a workforce of approximately 60 full-time employees. As a clinical-stage entity, RAPT Therapeutics has not yet commercialized approved products and generates no meaningful product revenue. The company was incorporated in Delaware in 2015 and was formerly known as FLX Bio, Inc. before rebranding in May 2019. Since 2023, RAPT Therapeutics operates as a subsidiary of Bristol-Myers Squibb Company, which acquired the firm to expand its immunology-focused pipeline. The company focuses exclusively on the United States market for its development activities.